A strong quarter, a new board committee, and a pending innovation webinar frame a potential inflection for the specialty chemical maker.
ASH · Earnings Call · 2026-07-29
From Disruption to Discipline
Ashland's fiscal Q3 (period ended June 30, 2026) shows a company finally turning a corner after a year of internal operational setbacks. Sales rose 7% year-over-year to $497 million, with volume up 6% across all business units—a broad-based rebound that CEO Guillermo Novo framed as evidence that “demand remained healthy across our core businesses.” That strength translated into Pricing realization, with pricing up ~1% year-over-year and sequentially improving roughly 300 basis points. Crucially, the company is now generating strong free cash flow: $103 million on an ongoing basis, representing >90% conversion, while inventory is down nearly $80 million fiscal year-to-date.
Yet the quarter still carries the scars of earlier production challenges. Adjusted EBITDA slipped to $109 million from $113 million a year ago, and margins compressed ~250 basis points as lower production rates and incentive compensation normalization offset volume and mix gains. William Whitaker, CFO, was candid: “Profitability continued to reflect the impact of lower production rates earlier in the year.” The sequential improvement, however, suggests the trough is behind them. “We have captured all the inflation” — Guillermo Novo, Chairman and CEO · 2026-07-29 (Guillermo Novo, Q&A) — a claim that now has tangible proof in the pricing data.
Overall, we delivered a strong third quarter that reflected strong demand, disciplined commercial execution and healthy free cash flow generation.
Governance: A New Board, A New Mandate
The most significant strategic shift came from the boardroom—not the plant floor. Yesterday, Ashland announced a cooperation agreement with Ancora, adding two independent directors (Peter Thomas and Alan Spizzo) and forming a capital allocation advisory committee. Guillermo Novo reinforced that the board has long been reviewing strategy, but the new committee is designed to “bring additional rigor and objectivity to our capital allocation strategy.” “We want to make sure that we have options to create value in multiple directions.” — Guillermo Novo, Chairman and CEO · 2026-07-29 This is a fresh, company-unique theme—distinct from the recurring operational focus and directly connected to the committee that appeared in this quarter's keywords for the first time.
The market has responded: the stock has risen ~29% over the last 90 trading days, far outpacing the broader specialty chemical group. This rally aligns with the board changes and the improving fundamental setup.
Innovation as the Next Catalyst
Beyond operational fixes, Ashland continues to lean into its technology platform and high-value applications. The high purity excipient strength in Life Sciences—up double digits—and the pending launch of a GLP-1-oriented permeation enhancer in August are part of a pipeline that Guillermo Novo calls “extremely exciting.” The company will host an innovation webinar on September 17 to detail its new platforms, which address markets like silicone replacement in personal care (an $800 million opportunity) and TiO2 efficiency in coatings. “You will see in the coming weeks... we are launching a permeation enhancer” — John Willis, Chief Financial Officer (CFO) · 2025-05-01 (Alessandra Faccin, Life Sciences leader).
The fundamentals support the narrative. Effective net cash improved 18% year-over-year to -$711 million, as the company works to rebuild balance sheet strength. Yet margins remain below peak: operating margin sits at 8.1%, down 2.6pp year-over-year, though the trend is positive. The focus on pricing and cost optimization is expected to lift margins in Q4 and into fiscal 2027, with management guiding to another step-up in profitability.
What Has Really Changed?
Three distinct shifts define this report:
1. Operational issues (Calvert City, Hopewell) are now behind or in the rearview, allowing absorption and commercial execution to take primacy.
2. Pricing actions, which management has touted for two years, are finally flowing through—a sequential 300bps improvement is concrete evidence.
3. The board is actively engaging with shareholder activists to formalize a capital allocation framework, opening the door to potential portfolio actions or enhanced shareholder returns.
“A lot of the new innovations that the team is doing... we feel very confident in the profitable growth potential.” — Guillermo Novo, Chairman and CEO · 2026-07-29 (Guillermo Novo, Q&A)
Ashland is no longer just a story of operational recovery—it is a company repositioning itself for sustained value creation. With the stock up 28.8% in three months and a clear line of sight to margin expansion, the market is pricing in a turnaround that has moved from promise to progress.